Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease

Neuroscience Research

Volumn 66, Issue 3, 2010, Pages 256-264

  Delattre, Ana Marcia ^a   Kiss, Ágata ^a   Szawka, Raphael E ^b   Anselmo Franci, Janete A ^b   Bagatini, Pamela Brambilla ^c   Xavier, Léder Leal ^c   Rigon, Paula ^d   Achaval, Matilde ^d   Iagher, Fabíola ^a   de David, Cíntia ^e   Marroni, Norma A P ^e   Ferraz, Anete Curte ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

6 OHDA; Dopamine; Fish oil; Motor deficits; Omega 3; Parkinson's disease; Polyunsaturated fatty acids

Indexed keywords

APOMORPHINE; DOCOSAHEXAENOIC ACID; DOPAMINE; FATTY ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OXIDOPAMINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; IMMUNOREACTIVITY; LIPID COMPOSITION; LIPID PEROXIDATION; MALE; MEDIAL FOREBRAIN BUNDLE; METABOLITE; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SUPPLEMENTATION; VENTRAL TEGMENTUM;

ANIMALS; APOMORPHINE; BRAIN; CELL MEMBRANE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; FATTY ACIDS, OMEGA-3; LIPID PEROXIDATION; MALE; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RANDOM ALLOCATION; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 77049100951     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2009.11.006     Document Type: Article

References (61)

1. Abushufa R., Reed P., Weinkove C. Fatty acids in erythrocytes measured by isocratic HPLC. Clin. Chem. 1994, 40:1707-1712.
2. Bazan N.G. Cell survival matters: docosahexaenoic acid signaling, neuroprotetion and photoreceptors. Trends Neurosci. 2006, 29:263-271.
3. Bezard E., Gross C.E., Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 2003, 26:215-221.
4. Blondeau N., Widmann C., Lazdunski M., Heurteaux C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience 2002, 109:231-241.
5. Blum D., Torch S., Lamgeng N., Nissou M.F., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
6. Bourre J.M., Francois M., Youyou A., Dumont O., Piciotti M., Pascal G. The effects of dietary α-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. J. Nutr. 1989, 119:880-1892.
7. Bousquet M., Saint-Pierre M., Julien C., Salem N., Cicchetti F., Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acids on toxin-induced neuronal degeneration in animal model of Parkinson's disease. FASEB J. 2008, 22:1213-1225.
8. Bowen R.A.R., Clandinin M.T. Dietary low linolenic acid compared with docosahexaenoic acid alter synaptic plasma membrane phospholipids fatty acid composition and sodium-potassium ATPase kinetics in developing rats. J. Neurochem. 2002, 83:764-774.
9. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 1978, 52:302-310.
10. Calon F., Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative disease: evidence from animal studies. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:287-293.
11. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
12. Cansev M., Ulus I.H., Wang L., Maher T.J., Wurtman R.J. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci. Res. 2008, 62:206-209.
13. Clandinin M.T. Brain development and assessing the supply of polyunsaturated fatty acid. Lipids 1999, 34:131-135.
14. Da Silva T.M., Munhoz R.P., Alvarez C., Naliwaiko K., Kiss A., Andreatini R., Ferraz A.C. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J. Affect. 2008, 111:351-359.
15. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
16. De Lau L.M.L., Bornebroek M., Witteman J.C.M., Hofman A., Koudstaal P.J., Breteler M.M.B. Dietary fatty acids and the risk of Parkinson disease. Neurology 2005, 64:2040-2045.
17. Debeir T., Ginestet L., François C., Laurens S., Martel J.C., Chopin P., Marien M., Colpaert F., Raisman-Vozari R. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp. Neurol. 2005, 193:444-454.
18. Díaz M.R., Abdala P., Barroso-Chinea P., Obeso J., González-Hernández T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav. Brain Res. 2001, 122:79-92.
19. Emborg M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 2004, 139:121-143.
20. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 2007, 205:295-312.
21. Farkas E., Wilde M.C., Kiliaan A.J., Meijer J., Keijser J.N., Luiten P.G.M. Dietary long chain PUFAs differentially affect hippocampal muscarinic 1 and serotonergic 1A receptors in experimental cerebral hypoperfusion. Brain Res. 2002, 954:32-41.
22. Fedorova I., Salem N. Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:271-289.
23. Ferraz A.C., Xavier L.L., Hernandes S., Sulzbach M., Viola G.G., Anselmo- Franci J.A., Achaval M., Da Cunha C. Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine. Brain Res. 2003, 986:200-205.
24. Ferraz A.C., Matheussi F., Szawka R.E., Rizelio V., Delattre A.M., Rigon P., Hermel E.E.S., Xavier L.L., Achaval M., Anselmo-franci J.A. Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle. Neurochem. Res. 2008, 33:1238-1246.
25. Ferro M.M., Belissimo M.I., Anselmo-Franci J.A., Angellucci M.E.M., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods 2005, 148:78-87.
26. Folch J., Lees M., Stanley G.H.S. A simple method for the isolation and purification of total lipid from animal tissues. J. Biol. Chem. 1957, 226:497-509.
27. Gillies, G.E., McArthur, S., in press. Independent influences of sex of systemic and central origin in a rat model of Parkinson's disease: a contribution to sex-specific neuroprotection by estrogens. Horm. Behav., doi: 10.1016/j.yhbeh.2009.06.002.
28. Hashimoto M., Hossain S., Shimada T., Sugioka K., Yamasaki H., Fujii Y., Ishibashi Y., Oka J., Shido O. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J. Neurochem. 2002, 81:1084-1091.
29. Högyes E., Nyakas C., Kiliaan A., Farkas T., Penke B., Luiten P.G.M. Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 2003, 119:999-1012.
30. Horrocks L.A., Farooqui A.A. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70:361-372.
31. Howells F.M., Russel V.A., Mabandla M.V., Kellaway L.A. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease. Behav. Brain Res. 2005, 165:210-220.
32. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res. 2005, 162:1-10.
33. Julien C., Berthiaume L., Hadj-Tahar A., Rajput A.H., Bédard P.J., Di Paolo T., Julien P., Calon F. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patient and parkinsonian monkeys. Neurochem. Int. 2006, 48:404-414.
34. Jump D.B. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr. Opin. Lipidol. 2002, 13:155-164.
35. Lane E.L., Cheetham S.C., Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well therapeutic effects in Parkinson's disease. Exp. Neurol. 2006, 197:284-290.
36. Lauritzen L., Hansen H.S., Jorgensen M.H., Michaelsen K.F. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog. Lipid Res. 2001, 40:1-94.
37. Levant B., Radel J.D., Carlson S.E. Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation. Behav. Brain Res. 2004, 152:49-57.
38. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin-phenol reagents. J. Biol. Chem. 1951, 193:265-275.
39. Luchtman D.W., Shao D., Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol. Behav. 2009, 98:130-138.
40. Mazza M., Pomponi M., Janiri L., Bria P., Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric disease: an overview. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:12-26.
41. McNamara R.K., Carlson S.E. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:329-349.
42. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennet D.A., Wilson R.S., Aggarval N., Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60:940-946.
43. Naliwaiko K., Araújo R.L.F., Fonseca R.V., Castilho J.C., Andreatini R., Bellíssimo M.I., Oliveira B.H., Martins E.F., Curi R., Fernandes L.C., Ferraz A.C. Effects of fish oil on the central nervous system: a new potential antidepressant. Nutr. Neurosci. 2004, 7:91-99.
44. Nishiyama-Naruke A., Souza J.A., Carnellós M., Curi R. HPLC determination of underivatized fatty acids saponified at 37°C analysis of fatty acids in oil and tissues. Anal. Lett. 1998, 31:2565-2576.
45. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am. J. Psychiatry 2006, 163:969-978.
46. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego.
47. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot. Essent. Fatty Acids 2003, 69:477-485.
48. Ross B.M. ω-3 Fatty acid deficiency in major depressive disorder is caused by the interaction between diet and a genetically determined abnormality in phospholipids metabolism. Med. Hypotheses 2007, 68:515-524.
49. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog. Neurobiol. 1998, 56:591-611.
50. Samadi P., Grégoire L., Rouillard C., Bédard P., Di Paolo T., Lévesque D. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann. Neurol. 2006, 59:282-288.
51. Sánchez-Iglesias S., Rey P., Méndez-Álvarez E., Labandeira-García J.L., Soto-Otero R. Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. Neurochem. Res. 2007, 32:99-105.
52. Schapira A.H.V., Bezard E., Brotchie J., Calon F., Collingridge G.L., Ferger B., Hengerer B., Hirsch E., Jenner P., Le Novère N., Obeso J.A., Schwarzschild M.A., Spampinato U., Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature 2006, 5:845-854.
53. Scott B.L., Bazan N.G. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:2903-2907.
54. Touchon J.C., Moore C., Frederickson J., Meshul C.K. Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-trated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations. Synapse 2004, 51:287-298.
55. Truong L., Allbutt H., Kassiou M., Henderson J.M. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav. Brain Res. 2006, 169:1-9.
56. Urquiza A.M., Liu S., Sjöberg M., Zetterström R.H., Griffiths W., Sjövall J., Perlmann T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000, 29:2140-2144.
57. Weinstock-Guttman B., Baien M., Park Y., Feichter J., Lee-Kwen P., Gallagher E., Venkatraman J., Meksawan K., Deinehert S., Pedergast D., Awad A.B., Ramanathan M., Munschauer F., Rudick R. Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot. Essent. Fatty Acids 2005, 73:397-404.
58. Xavier L.L., Viola G.G., Ferraz A.C., Da Cunha C., Deonizio J.M.D., Netto C.A., Achaval M. A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res. Protoc. 2005, 16:58-64.
59. Yavin E., Brand A., Green P. Docosahexaenoic acid abundance in the brain: a bioevidence to combat oxidative stress. Nutr. Neurosci. 2002, 5:149-157.
60. Youdim K.A., Martin A., Joseph J.A. Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 2000, 18:383-399.
61. Yuan H., Sarre S., Ebinger G., Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat model of Parkinson's disease. J. Neurosci. Methods 2005, 144:35-45.